Arcturus Therapeutics, Inc.
Arcturus Therapeutics, Inc.
Explore linked clinical trials.3 results ยท Page 1 of 1
Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| Self-Amplifying mRNA COVID-19 Vaccine (LUNAR-COV19) Versus Comirnaty Vaccine in Adult Hematopoietic Cell Transplant Patients | Hematopoietic and Lymphatic System Neoplasm | Not yet recruiting | Phase 2 | 2026-09-17 | NCT07390968 | |
| Safety, Tolerability and Efficacy Study of ARCT-032 in People With Cystic Fibrosis | Congenital, Hereditary, and Neonatal Diseases and Abnormalities, Digestive System Diseases, Infant, Newborn, Diseases, cystic fibrosis, hereditary disease, lung disorder, pancreas disorder, respiratory system disorder | Recruiting | Phase 2 | 2026-05-08 | NCT06747858 | |
| A Study to Evaluate the Pharmacodynamics and Safety of ARCT-810 in Participants With OTCD | Brain Diseases, Metabolic, Brain Diseases, Metabolic, Inborn, Congenital, Hereditary, and Neonatal Diseases and Abnormalities, Nutritional and Metabolic Diseases, X-linked disease, brain disorder, central nervous system disorder, hereditary disease, inborn disorder of amino acid metabolism, inborn errors of metabolism, metabolic disease, nervous system disorder, ornithine carbamoyltransferase deficiency, urea cycle disorder | Recruiting | Phase 2 | 2025-03-17 | NCT06488313 |